2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/16/17Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
‒ NeoCart® Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 ‒ ‒ Strong Performance in all Areas of the Business in 2016 ‒ ‒ Financing Completed in the Third Quarter of 2016 Expected to Fund Company to Phase 3 Data ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) --  Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and co... 
Printer Friendly Version
03/09/17Histogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
– Data demonstrate Histogenics’ Tissue Engineered Cartilage Constructs Exhibit Mechanical Properties Approaching Native Human Cartilage as Early as Three Weeks in Culture and Prior to Implantation –  – First Study to Use Three Mechanical Tests to Examine and Understand the Performance of Repaired Cartilage in Accordance with FDA Guidance – WALTHAM, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on deve... 
Printer Friendly Version
03/02/17Histogenics Corporation to Announce 2016 Financial Results on March 16, 2017
WALTHAM, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter and year ended December 31, 2016, on March 16, 2017 before the market opens.  Histogenics’ management will host a conference call on Thursday, March 16, 2017 at 8:30 a.m. EDT. A question-and-answer session will f... 
Printer Friendly Version
02/23/17Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming healthcare investor conferences.  Cowen and Company 37th Annual Health Care Conference – Boston, MA (March 6-8, 2017) Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Mond... 
Printer Friendly Version
01/11/17Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
– Data demonstrate significant improvement in cartilage quality over first 24 months after treatment, with stabilization and maturation thereafter out to 60 months –  – Improvements in cartilage quality were accompanied by consistent and statistically significant improvements in patient reported clinical outcomes as early as 3 to 6 months after implantation –  – Data underscore potential to provide a faster and more durable recovery for patients with cartilage defects in the knee – WALTHAM, M... 
Printer Friendly Version